Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

摘要

ARID1 subunits are tightly associated with the prognosis of NSCLC. a. The prevalence of ARID1 subunits mutations in NSCLC patients according to the cBioPortal for Cancer Genomics; b. The relationship between ARID1A expression and the prognosis of NSCLC patients; c. The relationship between ARID1B expression and the prognosis of NSCLC patients